세계의 허브 나노의약품 시장 : 유형별, 원료별, 용도별, 지역별(-2032년)

Global Herbal Nanomedicines Market Research Report by Type (Polymeric Herbal Nanoparticles, Solid Lipid Nanoparticles, Phytosomes, Nano-Micelles, Self-nano Emulsifying Drug Delivery System, Nanofibers, Others), by Source (Ginseng, Turmeric, Aloe Vera, Ginger, Others), by Application (Cancer, Cardiovascular Diseases, Neurological Disorders, Others), by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032

Industry Overview

The market was estimated to be USD 5,981.97 million in 2022 and is expected to reach a value of USD 14,946.60 million by 2032, growing steadily at a CAGR of 8.55% by the end of the forecast period. Herbal nanomedicines involve the use of nano-sized carriers to deliver active ingredients from medicinal plants with greater precision and efficiency. This approach helps overcome limitations like poor solubility or rapid degradation of herbal compounds, offering advanced treatment options with improved safety.

The rising demand for natural and herbal nanomedicines is one of the major drivers of the global market trend, which is especially confirmed by the consumer preference for safe, effective, and holistic health solutions. Nanotechnology not only makes the intake of phytochemicals such as curcumin and resveratrol more effective but also gives a perfect solution to the problem of their poor solubility and low bioavailability.

Major Company Development

Through the use of research and production technologies, the company's objective will be to revamp the performance of the bioactive ingredient while preserving quality in natural innovation. This INDENA approach makes it possible for the company to create healthcare customer value propositions that stand out, while also achieving a strong position among the nutraceutical world partners.

Key Players

Major competitors in the global herbal nanomedicines market are Oneplanet Nutrition, Indena S.p.A., Codeage LLC, Nutriherbs, Basic Brands Inc., Nanoceutical Solutions, Vibdrugs Biosciences, OIC New, Herbalife Ltd, and Evolu Research.

Report Attribute Details

Market Size 2022 USD 5,981.97 Million

Market Size 2032 USD 14,946.60 Million

CAGR (2023-2032) 8.55%

Base Year 2022

Market Forecast Period 2023-2032

Industry Segmentations

By Type: Polymeric Herbal Nanoparticles - 8.78%, Solid Lipid Nanoparticles - 9.36%.

By Source: Ginseng - 8.95%, Turmeric - 9.71%.

By Application: Cancer - 9.86%, Cardiovascular Diseases - 7.41%.

Regional Analysis

North America represents stable growth where the trend is fueled by innovation and the presence of market leaders. The U.S. contributes over 80% of regional sales, where demand for sustainable plant-based alternatives is the main driver. Led by the U.S. (USD 1,910.59 million) and Canada (USD 409.21 million), North America dominates the market, supported by consumer preference for natural therapies and advanced research capabilities.

Europe is leveraging its well-developed infrastructure and regulatory frameworks that are favorable for herbal medicine integration. Germany and the UK, with their high consumer adoption rates, are the most prominent markets in this regard. Germany (USD 396.00 million), the UK (USD 294.45 million), and France (USD 250.55 million) highlight Europe's robust demand, fueled by regulatory support and growing adoption of sustainable nanomedicine solutions.

The Asia-Pacific is the most dynamic market that has been growing quickly than the others. It is said that India will have the largest CAGR of 13.30% in this sector. China (USD 340.53 million), Japan (USD 293.81 million), and India (USD 241.04 million) underscore APAC's rapid rise, supported by traditional medicine integration and expanding nanotechnology research.

Emerging markets in South America and the Middle East are boosting regional demand through investments in healthcare modernization. Brazil and GCC countries show promise for herbal nanomedicine adoption. Still, regulatory uncertainty and limited infrastructure restrain overall market acceleration.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING DEMAND FOR NATURAL AND HERBAL-BASED NANOMEDICINE
  • 4.2.2 GROWING GERIATRIC POPULATION
• 4.3 RESTRAINTS
  • 4.3.1 LACK OF AWARENESS ASSOCIATED WITH HERBAL NANOMEDICINE
• 4.4 OPPORTUNITY
  • 4.4.1 ONGOING RESEARCH AND CLINICAL TRIALS ON HERBAL NANOMEDICINE

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL HERBAL NANOMEDICINE MARKET
• 5.3 TRENDS IN HERBAL NANOMEDICINES
  • 5.3.1 BENEFITS OF NANOSIZING
  • 5.3.2 COMBINATION THERAPY
  • 5.3.3 SAFETY AND BIOCOMPATIBILITY
  • 5.3.4 CLINICAL TRIALS AND COMMERCIALIZATION

6 GLOBAL HERBAL NANOMEDICINE MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 POLYMERIC HERBAL NANOPARTICLES
• 6.3 SOLID LIPID NANOPARTICLES
• 6.4 PHYTOSOMES
• 6.5 NANO-MICELLES
• 6.6 SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEM
• 6.7 NANOFIBERS
• 6.8 OTHERS

7 GLOBAL HERBAL NANOMEDICINE MARKET, BY SOURCE

• 7.1 OVERVIEW
• 7.2 GINSENG
• 7.3 TURMERIC
• 7.4 ALOE VERA
• 7.5 GINGER
• 7.6 OTHERS

8 GLOBAL HERBAL NANOMEDICINE MARKET, BY APPLICATION

• 8.1 OVERVIEW
• 8.2 CANCER
• 8.3 CARDIOVASCULAR DISEASES
• 8.4 NEUROLOGICAL DISORDERS
• 8.5 OTHERS

9 GLOBAL HERBAL NANOMEDICINE MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST & AFRICA
  • 9.5.2 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2022
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

11 COMPANY PROFILES

• 11.1 EVOLU RESEARCH
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 KEY STRATEGIES
• 11.2 CODEAGE LLC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PROUDCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 NUTRIHERBS
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 BASIC BRANDS INC.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 HERBALIFE INTERNATIONAL OF AMERICA, INC.
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FNANCIAL OVERVIEW
  • 11.5.3 SERVICES OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 INDENA S.P.A
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 NANOCEUTICAL SOLUTIONS
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGY
• 11.8 VIBDRUGS BIOSCIENCES
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 ONE PLANET NUTRITION
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 SWOT ANALYSIS
  • 11.9.6 KEY STRATEGY
• 11.10 OIC NEW
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

12 DATA CITATIONS